{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:48:45Z","timestamp":1787647725442,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Marato TV3 Foundation","award":["20141830"],"award-info":[{"award-number":["20141830"]}]},{"name":"Torrons Vicens Foundation","award":["PFNR0144"],"award-info":[{"award-number":["PFNR0144"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejpn.2020.11.001","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T18:32:27Z","timestamp":1604773947000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["E.U. paediatric MOG consortium consensus: Part 3 \u2013 Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-6171","authenticated-orcid":false,"given":"Tha\u00eds","family":"Armangue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali\u00e9nor","family":"de Chalus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Laetitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlette L.","family":"Bruijstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Flet-Berliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Adamsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rostasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinze F.","family":"Neuteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejpn.2020.11.001_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2352-4642(18)30026-9","article-title":"MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study","volume":"2","author":"Fadda","year":"2018","journal-title":"Lancet Child Adolesc Heal"},{"issue":"8","key":"10.1016\/j.ejpn.2020.11.001_bib3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult. Scler. J"},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1474-4422(11)70045-X","article-title":"Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study","volume":"10","author":"Banwell","year":"2011","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib8","article-title":"E.U. paediatric MOG consortium consensus: Part 1 \u2013 Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.11.001_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2006.06.028","article-title":"Antibodies as biological markers for pathophysiological processes in MS","volume":"180","author":"Reindl","year":"2006","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1756285611433772","article-title":"Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more","volume":"5","author":"Mayer","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ejpn.2020.11.001_bib11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1371\/journal.pone.0079083","article-title":"An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays","volume":"8","author":"Hoftberger","year":"2013","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib12","first-page":"1349","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J.\u00a0Neurol."},{"issue":"22","key":"10.1016\/j.ejpn.2020.11.001_bib13","doi-asserted-by":"crossref","first-page":"e2302","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib15","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"issue":"11","key":"10.1016\/j.ejpn.2020.11.001_bib16","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A\u00a0multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib17","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib19","doi-asserted-by":"crossref","first-page":"101939","DOI":"10.1016\/j.msard.2020.101939","article-title":"Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases","volume":"40","author":"Kim","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejpn.2020.11.001_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib23","first-page":"265","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","author":"Baumann","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib24","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult. Scler. J"},{"issue":"9","key":"10.1016\/j.ejpn.2020.11.001_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejpn.2020.11.001_bib28","series-title":"Antibodies to Native Myelin Oligodendrocyte Glycoprotein in Children with Inflammatory Demyelinating Central Nervous System Disease","first-page":"833","author":"Brilot","year":"2009"},{"issue":"20","key":"10.1016\/j.ejpn.2020.11.001_bib29","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.ejpn.2020.11.001_bib30","first-page":"e1867","article-title":"Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease","volume":"93","author":"Pedre\u00f1o","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"10.1016\/j.ejpn.2020.11.001_bib31","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti\u2013myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2019","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ejpn.2020.11.001_bib33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Probstel","year":"2011","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.ejpn.2020.11.001_bib34","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.ejpn.2020.11.001_bib37","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1352458512470310","article-title":"Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica","volume":"19","author":"Rost\u00e1sy","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejpn.2020.11.001_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti\u2013myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib39","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejpn.2020.11.001_bib40","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/1352458512466317","article-title":"Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients","volume":"19","author":"Huppke","year":"2013","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib41","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/ene.13602","article-title":"Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome","volume":"25","author":"Wong","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib42","article-title":"paediatric MOG consortium consensus: Part 5 \u2013 Treatment of paediatricmyelin oligodendrocyte glycoprotein antibody-associated disorders","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J.\u00a0Neurochem."},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib44","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/glia.1111","article-title":"T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"36","author":"Iglesias","year":"2001","journal-title":"Glia"},{"issue":"9","key":"10.1016\/j.ejpn.2020.11.001_bib45","article-title":"Myelin oligodendrocyte glycoprotein \u2013 specific T and B cells cooperate to induce a Devic-like disease in mice","volume":"116","author":"Bettelli","year":"2006"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2353\/ajpath.2007.060893","article-title":"Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies","volume":"170","author":"Burrer","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1352458518823486","article-title":"Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis","volume":"26","author":"Rossor","year":"2020","journal-title":"Mult. Scler. J"},{"issue":"9","key":"10.1016\/j.ejpn.2020.11.001_bib48","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib50","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","article-title":"Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases","volume":"191","author":"Mayer","year":"2013","journal-title":"J.\u00a0Immunol."},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib51","first-page":"3594","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"191","author":"Peschl","year":"2017","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0300985817712794","article-title":"Experimental models of autoimmune demyelinating diseases in nonhuman primates","volume":"55","author":"Stimmer","year":"2018","journal-title":"Vet. Pathol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/glia.1101","article-title":"Basic principles of immunological surveillance of the normal central nervous system","volume":"36","author":"Hickey","year":"2001","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1440-1789.2010.01167.x","article-title":"Immune surveillance of the normal human CNS takes place in dependence of the locoregional blood-brain barrier configuration and is mainly performed by CD3+\/CD8+ lymphocytes","volume":"31","author":"Loeffler","year":"2011","journal-title":"Neuropathology"},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ni.1716","article-title":"C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE","volume":"10","author":"Reboldi","year":"2009","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ana.24242","article-title":"The formation of inflammatory demyelinated lesions in cerebral white matter","volume":"76","author":"Maggi","year":"2014","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/acn3.194","article-title":"The primate autoimmune encephalomyelitis model; a bridge between mouse and man","volume":"2","author":"\u2018t Hart","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2020.11.001_bib59","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.175.7.4761","article-title":"Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody","author":"Hart","year":"2005","journal-title":"J.\u00a0Immunol."},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib60","first-page":"4761","article-title":"Multiple sclerosis - a response-to-damage model","volume":"175","author":"\u2019t Hart","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejpn.2020.11.001_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fimmu.2013.00145","article-title":"The primate EAE model points at EBV-infected B cells as a preferential therapy target in multiple sclerosis","volume":"4","author":"\u2019T Hart","year":"2013","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/eji.201141863","article-title":"Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG 34-56 peptide in incomplete adjuvant","volume":"42","author":"Jagessar","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ebiom.2019.08.052","article-title":"Intradermal vaccination prevents anti-MOG autoimmune encephalomyelitis in macaques","volume":"47","author":"Fovet","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1084\/jem.20110399","article-title":"Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells","volume":"209","author":"Li","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"issue":"12","key":"10.1016\/j.ejpn.2020.11.001_bib65","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2018.03.025","article-title":"T\u00a0cell receptor-regulated TGF-\u03b2 type I receptor expression determines T cell quiescence and activation","volume":"48","author":"Tu","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib67","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-019-1637-7","article-title":"Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases","volume":"16","author":"Serguera","year":"2019","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib68","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1212\/NXI.0000000000000538","article-title":"Anti-MOG encephalitis mimicking small vessel CNS vasculitis","volume":"6","author":"Patterson","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib69","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib70","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"23","key":"10.1016\/j.ejpn.2020.11.001_bib71","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1212\/WNL.0b013e318200d80c","article-title":"Absence of cortical demyelination in neuromyelitis optica","volume":"75","author":"Popescu","year":"2010","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.11.001_bib72","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jneuroim.2011.01.010","article-title":"Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin","volume":"233","author":"Obermeier","year":"2011","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib73","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ana.410130410","article-title":"Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases","volume":"13","author":"Chu","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2020.11.001_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jnnp.2008.159483","article-title":"Cerebrospinal fluid study in paraneoplastic syndromes","volume":"81","author":"Psimaras","year":"2010","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/jnnp-2014-308984","article-title":"Overlapping CNS inflammatory diseases: differentiating features of NMO and MS","volume":"86","author":"Jury\u0144czyk","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib76","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib77","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1212\/NXI.0000000000000528","article-title":"Real-world validation of the 2017 McDonald criteria for pediatric MS","volume":"6","author":"Wong","year":"2019","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib78","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jpeds.2003.10.056","article-title":"First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability","volume":"144","author":"Mikaeloff","year":"2004","journal-title":"J.\u00a0Pediatr."},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.11.001_bib79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"10","key":"10.1016\/j.ejpn.2020.11.001_bib80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib81","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458518775303","article-title":"High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome","volume":"25","author":"van der Vuurst de Vries","year":"2019","journal-title":"Mult. Scler. J"},{"issue":"11","key":"10.1016\/j.ejpn.2020.11.001_bib82","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/jnnp-2018-320287","article-title":"Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders","volume":"90","author":"Mariotto","year":"2019","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.ejpn.2020.11.001_bib83","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib84","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awy021","article-title":"Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome","volume":"141","author":"Matute-Blanch","year":"2018","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.ejpn.2020.11.001_bib85","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1212\/WNL.0000000000008057","article-title":"Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes","volume":"93","author":"Wong","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib86","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1352458512458010","article-title":"CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome","volume":"19","author":"Khalil","year":"2013","journal-title":"Mult. Scler. J"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.11.001_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jneuroim.2013.06.010","article-title":"Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis","volume":"262","author":"Fialov\u00e1","year":"2013","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib88","first-page":"126","article-title":"Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome","volume":"87","author":"Disanto","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"22","key":"10.1016\/j.ejpn.2020.11.001_bib89","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib90","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"issue":"8","key":"10.1016\/j.ejpn.2020.11.001_bib91","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult. Scler. J"},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib92","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1212\/NXI.0000000000000749","article-title":"Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis","volume":"7","author":"Reinert","year":"2020","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"issue":"4","key":"10.1016\/j.ejpn.2020.11.001_bib93","article-title":"Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status","volume":"3","author":"Mariotto","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib94","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"issue":"1","key":"10.1016\/j.ejpn.2020.11.001_bib95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/83679","article-title":"Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease","volume":"27","author":"Brenner","year":"2001","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib96","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib97","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ane.12239","article-title":"Assessing tissue damage in multiple sclerosis: a biomarker approach","volume":"130","author":"Burman","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"13","key":"10.1016\/j.ejpn.2020.11.001_bib98","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ejpn.2020.11.001_bib99","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/jnnp-2015-312676","article-title":"Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies","volume":"87","author":"Kaneko","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.ejpn.2020.11.001_bib100","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3390\/ijms19082408","article-title":"Tau in oligodendrocytes takes neurons in sickness and in health","volume":"19","author":"Lopresti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib101","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1191\/1352458506ms1288sr","article-title":"Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis","volume":"12","author":"Guimar\u00e3es","year":"2006","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib102","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/bmm-2017-0374","article-title":"BDNF and Tau as biomarkers of severity in multiple sclerosis","volume":"12","author":"Islas-Hernandez","year":"2018","journal-title":"Biomarkers Med."},{"issue":"7","key":"10.1016\/j.ejpn.2020.11.001_bib103","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D","article-title":"IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis","volume":"28","author":"Pietro","year":"1998","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.ejpn.2020.11.001_bib104","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.ejpn.2020.11.001_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149411","article-title":"B\u00a0cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination","volume":"11","author":"Kothur","year":"2016","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.ejpn.2020.11.001_bib106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-2003-41281","article-title":"Interleukin-6 and oligoclonal IgG synthesis in children with acute disseminated encephalomyelitis","volume":"34","author":"Dale","year":"2003","journal-title":"Neuropediatrics"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2020.11.001_bib107","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2006.03.020","article-title":"CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis","volume":"175","author":"Ishizu","year":"2006","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"8","key":"10.1016\/j.ejpn.2020.11.001_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072399","article-title":"Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases","volume":"8","author":"Wullschleger","year":"2013","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.ejpn.2020.11.001_bib109","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"16","key":"10.1016\/j.ejpn.2020.11.001_bib110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","article-title":"Tocilizumab treatment in severe recurrent anti-MOG-Associated optic neuritis","volume":"92","author":"Hayward-Koennecke","year":"2019","journal-title":"Neurology"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820302051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379820302051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:38:07Z","timestamp":1761071887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379820302051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":110,"alternative-id":["S1090379820302051"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.11.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"E.U. paediatric MOG consortium consensus: Part 3 \u2013 Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2020.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}